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Abstract
Perceived fatigue is a prominent symptom in patients with mitochondrial disease but to date its prevalence, impact and aetiology are poorly
understood. Our aim was to determine the prevalence and assess for comorbidities associated with clinically relevant fatigue in patients with
mitochondrial disease. A cross-sectional postal survey of patients with mitochondrial disease was undertaken using a validated self-completion,
patient-reported outcome measures (response rate: 60%; n = 132). The prevalence and perceived functional impact of experienced fatigue were
assessed using the Fatigue Impact Scale. Other putative biological mechanisms were evaluated using the Hospital Anxiety Depression scale and
Epworth sleepiness scale. Data were compared with those for healthy control subjects and patients with Myalgic Encephalopathy/Chronic Fatigue
Syndrome matched for age and gender. Sixty-two per cent of patients with mitochondrial disease reported excessive symptomatic fatigue (Fatigue
Impact Scale ≥ 40); whilst 32% reported severe, functionally limiting fatigue symptoms (Fatigue Impact Scale ≥ 80) comparable to perceived
fatigue in patients with Myalgic Encephalopathy/Chronic Fatigue Syndrome. Fatigue is common and often severe in patients with mitochondrial
disease irrespective of age, gender or genotype. Future evaluation of causal factors in mitochondrial disease-associated fatigue is warranted with
the potential to guide future treatment modalities.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license (http://creativecommons.org/licenses/
by/4.0/).
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1. Introduction
Perceived fatigue is a prominent and often debilitating
symptom in patients with mitochondrial disease yet the
prevalence, impact and aetiology of fatigue are poorly
understood. From an operational perspective, we define
perceived fatigue as an overwhelming sense of tiredness,
lack of energy or feeling of exhaustion [1] employing a
multifactorial approach; distinguishing this from physiological
fatigue in which the focus is muscle and its ability to generate
and maintain power. The premise of this study was to determine
the magnitude and impact of self-perceived fatigue in a large,
genetically heterogeneous group of patients with mitochondrial
disease, whilst evaluating putative biological mechanisms that
have been recognised in other neurological disorders and
chronic disease states.
1.1. Participants and methods
A postal survey of 215 adult patients with mitochondrial
disease attending our specialist outpatient clinic was
undertaken. Demographic data and disease burden established
using the Newcastle Mitochondrial Disease Adult Scale
(NMDAS) [2] were retrieved from clinical records. Myalgic
Encephalopathy/Chronic Fatigue Syndrome (CFS/ME) patients
(n = 74), as defined by the Centers for Disease Control and
Prevention 1994 Fukuda criteria [3], attending a specialist
out-patient care service were surveyed. Healthy control subjects
(n = 132) were Control subjects recruited through notices in
local press and hospitals asking for volunteers to participate in
research projects, with no selection made for the presence or
absence of fatigue and were matched for age and gender.
Institutional ethical approval was obtained.
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1.2. Symptom assessment tools
1.2.1. Assessing fatigue
The presence and perceived impact of fatigue was assessed
using the Fatigue Impact Scale (FIS) [4], a validated global
measure of fatigue comprising 40 questions covering three
domains: cognitive, physical and psychosocial. FIS scores
reflect the perceived functional impact of experienced fatigue
on these domains within the previous one month [5]. A score of
≥40 indicates excessive symptomatic fatigue and ≥80 severe,
symptomatic fatigue. To date, FIS has been validated for several
chronic disease states in which fatigue is recognised as a severe,
debilitating symptom including CFS/ME, multiple sclerosis,
chronic obstructive pulmonary disease, primary biliary
sclerosis and chronic hepatitis C [5].
1.2.2. Assessing for covariates of perceived fatigue
All participants completed the Hospital Anxiety Depression
scale (HAD) [6] to assess for depression (HAD-D) and anxiety
symptoms (HAD-A), and the Epworth sleepiness scale (ESS)
[7] to qualitatively measure daytime sleepiness. Disease burden
was established using the Newcastle Mitochondrial Disease
Adult Scale (NMDAS) [2].
1.3. Statistical analyses
All statistical analyses were performed using SPSS version
19. Chi square analysis was used to determine gender
differences in the study groups. The comparisons of FIS, HAD,
and ESS between the three groups were conducted using a One
Way analysis of variance (ANOVA), with a Tukey post-hoc test.
One Way ANOVA was also used to examine if genotype had an
impact on fatigue in patients with mitochondrial disease.
Multiple stepwise regression was used to determine whether
covariates analysed were significant predictors of fatigue.
2. Results
2.1. Patient and control characteristics
Of the initial 215 patients with mitochondrial disease
surveyed, one hundred and thirty-two questionnaires were
completed and returned (response rate: 60%) (Table 1): 91
females; mean age 52 years old (range 18–82); mean NMDAS
score 27 (±18). Control subjects (mean age 52 years; range
21–77) were age and gender matched for patients with
mitochondrial disease. Although CFS/ME patients (mean age
54 years; range 24–80) were age-matched; there were fewer
men (24%); however, the gender ratios between all three groups
were not significantly different (Chi square p = 0.401).
2.2. Prevalence and impact of fatigue
Fatigue was common in patients with mitochondrial disease
(mean FIS 58; SD 38) with 62% of patients reporting excessive
symptomatic fatigue (FIS ≥ 40) (Table 2). The mean FIS scores
among control subjects were 13 (SD 22) and 92 (SD 28) in
CFS/ME patients. The highest FIS scores in patients with
mitochondrial disease were comparable to those in patients
with CFS/ME (Fig. 1). The magnitude of symptomatic fatigue
and its perceived impact in patients with mitochondrial
disease correlated with disease burden (Pearson’s correlation
co-efficient r = 0.326, p < 0.0001), but was independent of
genotype (one-way between groups ANOVA; F (6,125) = 0.49,
p = 0.9). Using Spearman Rho (after Bonferroni correction) the
NMDAS domains that significantly correlated with FIS were
Table 1
Summary table of genotypes of 132 respondents with mitochondrial disease.
Genotype Number
mt-tRNA mutations
m.3243A>G MELAS mutation 39
m.8344A>G MERRF mutation 9
LHON 2
NARP 1
Others 12
Single-large scale mt-DNA deletion 26
Multiple mtDNA deletions
OPA1 3
POLG1 11
C10orf2 12
RRM2B 3
SPG7 1
Unspecified nuclear genetic defect 13
MELAS: mitochondrial encephalopathy, lactic acidosis and stroke-like
episodes; MERRF: myoclonic epilepsy with ragged red fibres; LHON: Leber’s
hereditary optic neuropathy; NARP: neuropathy, ataxia and retinitis
pigmentosa; mt: mitochondrial; tRNA: transfer RNA; OPA1: optic atrophy type
1; POLG1: polymerase gamma; C10orf2: chromosome 10 open reading frame
2; RRM2B: ribonucleotide reductase M2B (TP53 inducible); SPG7: spastic
paraplegia 7 gene mutations.
Table 2
The rank frequency of fatigue severity as assessed by FIS (Fatigue Impact
Scale).
FIS Rank FIS descriptive FIS scoring Results (n=)
0 No fatigue 0–10 16
1 Mild 10–37 31
2 Moderate 38–79 43
3 Severe 80–119 38
4 Very severe 129–160 4
Fig. 1. Distribution of Fatigue Impact severity (FIS) scores in patients with
mitochondrial disease (MM), healthy control volunteers (control); p < 0.001
and chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) patients.
FIS ≥ 40 indicates excessive symptomatic fatigue; FIS ≥ 80 indicates severe
symptomatic fatigue experienced in the past one month.
564 G.S. Gorman et al. /Neuromuscular Disorders 25 (2015) 563–566
swallowing, cutting food, dressing, hygiene, exercise tolerance,
gait and psychiatric. Notably all other domains were not
significant including myopathy (Supplementary Table S1).
Using each of the reported NMDAS myopathy scores (as
groups) and FIS scores in a one-way ANOVA, there was no
difference found between the myopathy categories (ANOVA,
p = 0.16) suggesting that fatigue is not an outcome of muscle
weakness score. There was no significant difference in the
impact of fatigue between men (independent-samples t-test,
M = 45.10, SD = 43.71) and women (M = 49.60, SD = 43.02;
t (336) = 0.881, p = 0.34) between the three groups.
2.3. Anxiety, depression and daytime sleepiness
Mean anxiety (HAD-A) scores were similar in both chronic
disease states (patients with mitochondrial disease; 8 (SD 5);
CFS/ME patients 8 (SD 5); control subjects; 5 (SD4)).There was
no significant difference in anxiety symptoms (HAD-A scores)
between patients with mitochondrial disease and CFS/ME
(One Way ANOVA, Tukey’s post-hoc test F (2,334) = 17.392,
p < 0.983); control subjects were significantly different from
both disease groups, overall ANOVA value (F (2,334) = 17.392,
p < 0.0001). Depressive symptoms (HAD-D) were less
prevalent in patients with mitochondrial disease (mean 5; SD 4)
compared to CFS/ME patients (mean 8; SD 4), but higher than
control subjects (mean 2; SD 3); one-way between groups
ANOVA (F (2,334) = 60.885, p < 0.0001). Twenty-seven per
cent of patients with mitochondrial disease reported excessive
daytime somnolence as assessed by ESS scores greater than 10
(mean ESS 6; SD 5). However, there was no significant
difference between ESS scores for all three groups (one-way
between groups ANOVA; F (2,335) = 1.65; p = 0.2).
2.4. Predictive model of fatigue
HAD-A, ESS, group, and HAD-D were retained as
significant predictors of FIS, whilst age and gender were not
significant predictors across the three groups. HAD-A, ESS,
group, and HAD-D accounted for half of the variance in fatigue
across all the participants who took part in the study (Stepwise-
regression analysis, adjusted R2 = 0.504), with a model
significance given as p < 0.001 (F (4,335) = 86.501).
3. Discussion
Kluger et al. [8] have recently proposed a unified taxonomy
for the evaluation of fatigue that provides a practical strategy
for conducting research of this common and often neglected
aspect of mitochondrial disease. Implementing this framework,
the aims of this study were to determine the prevalence and
nature of perceived fatigue in a large, genetically heterogeneous
group of patients with mitochondrial disease and systematically
assess potential covariates. We demonstrate that clinically
relevant fatigue is common and is often perceived to severely
impact on functionality in patients with mitochondrial disease
irrespective of age, gender and perhaps most surprisingly
genotype. Both the extent of fatigue experienced and its impact
in mitochondrial subjects were significantly greater than in
the age and gender matched control group. Sixty-two percent
of mitochondrial patients surveyed reported significant
symptomatic fatigue (FIS ≥ 40) with 32% reporting severe
symptomatic fatigue (FIS ≥ 80) with psychosocial and physical
domains more affected (p < 0.0001). Interestingly, although
there were no significant differences between male and female
patients with mitochondrial disease, in reported symptomatic
fatigue, male participants tended to report higher functional
limitation due to experienced fatigue which may be counter
intuitive and contrary to other chronic diseases in which fatigue
is a prominent symptom.
Prior to this study, although patients had been identified
clinically as having symptoms of fatigue, few had been
recognised to have such prominent fatigue comparable to that in
patients with CFS/ME. Potential bias may have arisen in that
respondents may have been only those with significant fatigue;
however, respondent disease burden and demographics are
strikingly representative of our patient cohort as a whole. Hence
it is likely that the severity and prevalence of fatigue symptoms
is decidedly under-recognised in patients with mitochondrial
disease.
Multiple factors have been implicated in influencing the
perception of fatigue including psychological parameters, sleep
disturbance and central and peripheral neurological dysfunction
[9]. Regression analysis suggested that anxiety, depression and
daytime sleepiness may be confounding factors of perceived
fatigue in patients with mitochondrial disease. However given
the high prevalence of fatigue in the absence of clinically
relevant anxiety or depression, in our patient cohort, it is
unlikely that the main driver of fatigue relates primarily to a
mood disorder. Similarly, although a third of those surveyed
scored greater than 10 on ESS, overall scores were not different
in patients with mitochondrial disease compared to control
subjects suggesting a clear dissociation between poor sleep
hygiene and perceived fatigue. Moreover, the ability of disease
burden to predict the presence and impact of fatigue in patients
with mitochondrial disease suggests that if we were able to
improve the biochemical defect or stop disease progression,
perceived fatigue would be less, irrespective of the underlying
fatigue mechanisms.
NMDAS domains that correlated with FIS were
predominantly activities of daily living (Supplementary Fig. S1)
reflecting the nature of the assessment tool employed (FIS),
namely, functional limitation due to experienced fatigue,
and the prevalence of symptoms in the disease group (patients
with mitochondrial disease) evaluated. The severity of
encephalopathy as defined by encephalopathy NMDAS sub
score was not associated with fatigue (Supplementary Table S1).
This is perhaps not surprising as stroke-like episodes and the
ensuing encephalopathy which are recognised, devastating
consequences of mitochondrial disease, affect only a relatively
small (10–15%) proportion of individuals who have inherited the
m.3243A>G mutation in mitochondrial DNA which is the most
common pathogenic point mutation in mitochondrial DNA [10].
In addition myopathy did not correlate with FIS and may reflect
the low prevalence of myopathic symptoms as assessed by
NMDAS in this cohort of patients. However, we concede that this
cohort of patients evaluated exhibit marked genotypic and
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phenotypic variability that may impact on current findings
particularly in relation to the absence of correlation of FIS with
genotype and propose that a future study with greater numbers
with more rare mitochondrial mutations may help correct for this
potential bias.
To our knowledge, this series is the largest prospective,
patient-reported outcome measure study to quantify the
prevalence and symptom severity of perceived fatigue and
evaluate possible covariates in patients with variable genotypic
mitochondrial disease. Although we have not assessed the
secondary impact of medications due to the low numbers
involved, important conclusions may be drawn. Fatigue is
common, frequently severe, and similar in magnitude to that
reported in other chronic neurological disorders [8]. Sleep
impairment can readily be distinguished from perceived fatigue
arising as a primary manifestation of mitochondrial disease
whilst there is clearly a more complex association between
perceived fatigue and mood disorders, warranting further
assessment.
The challenge now is to identify causal factors that may help
direct tailored pharmacological and non-pharmacological
symptomatic therapeutic strategies, including those that may
ameliorate the biochemical defect or halt progression; with
potential for a shared therapeutic paradigm with patients with
other chronic neurological disorders, exhibiting clinically
relevant fatigue.
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